Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiarrhythmic effects of flecainide

P Somani

    Clinical Pharmacology and Therapeutics
    |April 1, 1980
    PubMed
    Summary

    Flecainide, a new class I antiarrhythmic, effectively suppressed premature ventricular contractions (PVCs) and premature atrial contractions (PACs) in most patients. This study found flecainide to be safe with negligible side effects for short-term use.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Neonatal sepsis in a tertiary care center in central India: microbiological profile, antimicrobial sensitivity pattern and outcome.

    Journal of neonatal-perinatal medicine·2013
    Same author

    Rectal fistula due to ovarian teratoma.

    Endoscopy·2012
    Same author

    'Bull on neck': dissection of right common carotid artery.

    Journal of postgraduate medicine·2011
    Same author

    Hospital and public health agency relationships.

    Hospital topics·1992
    Same author

    Effect of atrial natriuretic peptide (8-33-Met ANP) in patients with hypertension.

    American journal of hypertension·1992
    Same author

    Evaluation of amiodarone free radical toxicity in rat hepatocytes.

    Toxicology letters·1991

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Class I antiarrhythmic agents are crucial for managing cardiac arrhythmias.
    • Flecainide represents a novel option within this drug class.

    Purpose of the Study:

    • To evaluate the short-term efficacy and safety of flecainide in patients with cardiac arrhythmias.
    • To determine flecainide's impact on premature ventricular contractions (PVCs) and premature atrial contractions (PACs).

    Main Methods:

    • A prospective study involving 10 hospitalized patients receiving intravenous flecainide.
    • Dosing involved initial boluses with potential for additional injections up to 5 mg/kg.
    • Patients presented with various arrhythmias including PVCs, atrial fibrillation (AF) with PVCs, and PACs.

    Main Results:

    • Flecainide suppressed PVCs in 7 out of 10 patients for an average of 13 hours.
    • Premature atrial contractions (PACs) were also suppressed.
    • Atrial fibrillation (AF) was not significantly affected by flecainide.
    • No significant changes in P-R, QRS, or Q-T intervals were observed.
    • Reported side effects were minimal, including transient tingling and skin warmth in one patient.

    Conclusions:

    • Flecainide demonstrates short-term efficacy in suppressing PVCs and PACs.
    • The drug exhibits a favorable safety profile with negligible side effects.
    • Flecainide may be a valuable therapeutic option for specific cardiac arrhythmias.

    Related Experiment Videos